News Sentiment

VVOS sentiment intelligence

Vivos Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.43 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -24.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Investor group takes 19.9% position in Vivos Therapeutics (VVOS)

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -24.5% over four weeks
Fair value -88.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
TradingView 7
TradingKey 4
MT Newswires 3
Investing.com Canada 2
StockStory 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 15
Balance sheet 7
Deals and strategy 5
Analyst action 2
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
Stock Titan Direct company coverage

Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms

Vivos Therapeutics plans a tradable rights offering to raise capital for operations, intending to distribute transferable subscription rights to shareholders as a dividend. The proposed terms indicate an initial exercise price for common shares at the greater of $1.25 or 20% abov

Tone
Neutral 50/100
Event
Capital return
Published
16 Jun 2026 21:09
Source
Stock Titan
Minichart Direct company coverage

Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea and Insomnia Treatment for Cardiovascular Patients

Vivos Therapeutics, Inc. has announced a strategic collaboration with South Palm Cardiovascular Associates, a multi-location Florida cardiology practice, to form AIM Florida, LLC. This partnership aims to integrate diagnostic and therapeutic clinical treatment services for cardio

Tone
Positive 76/100
Event
Deals and strategy
Published
16 Jun 2026 12:10
Source
Minichart
Stock Titan Direct company coverage

Vivos Therapeutics (NASDAQ: VVOS) inks AIM Florida deal with major cardiology group

Vivos Therapeutics (NASDAQ: VVOS) has partnered with South Palm Cardiovascular Associates (SPCVA) to establish AIM Florida, a management services organization focused on providing sleep apnea and insomnia care to cardiovascular patients in Florida. Vivos expects to hold at least

Tone
Positive 72/100
Event
Guidance
Published
16 Jun 2026 00:09
Source
Stock Titan